首頁 > 市場調查報告書 > 醫療設備

生技設備細胞培養

市場調查報告書

商品編碼

1410103

原代細胞培養市場：2023年至2028年預測

Primary Cell Culture Market - Forecasts from 2023 to 2028

出版日期: 2023年12月13日 | 出版商:

Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

原代細胞培養市場預計在預測期內複合年成長率為 8.59%。

在生物醫學研究中，原代細胞培養是直接分離和培養來自活體組織和器官的細胞的重要技術。透過解剖或切片檢查從組織中提取細胞，然後在適當的培養基中培養以保留其生理意義和天然特性。隨著研究各種細胞群的異質性增加，該方法為理解生物過程、藥理反應和毒理學結果提供了更準確的模型。

原代細胞培養市場的成長動力

推動原代細胞培養市場擴大的主要因素是糖尿病、癌症、感染疾病、自體免疫疾病、心血管疾病和腎臟疾病等慢性疾病發生率的上升。此外，由於這些患者疾病的增加而增加的研究工作正在推動原代細胞培養物的廣泛普及。

提高細胞和基因療法開發的使用率

對個人化治療的需求不斷增加，導致再生醫學的廣泛使用。這項因素進一步激發了原代細胞培養產業的活力。使用細胞和基因療法治療癌症、遺傳異常和自體免疫疾病等疾病具有廣闊的前景。原代細胞培養對其生長有重要作用。它是操縱或改變細胞或基因以恢復或增強其功能的行為。

癌症流行

由於癌症的流行，對原代細胞培養的需求正在擴大。例如，世界衛生組織預測，到2030年，全球癌症相關死亡人數將增加到近1,700萬人。此外，根據 2021 年 2 月的 ACS 日誌報道，2020 年全球整體有 1,020 萬人因癌症相關死亡，新增約 1,930 萬癌症病例。因此，隨著全球癌症發生率的上升，對創新治療方法的需求將會增加，預計這將推動原代細胞培養市場佔有率的成長。

對酵素分解的日益偏好預計將推動市場發展

由於酵素消化方法比替代初代細胞分離技術具有減少培養損傷、快速處理和代表性樣本高功率等優點，因此原代細胞培養市場的偏好正在上升。透過使用多種類型的酶，可以分解組織，同時產生大量初代細胞。此方法所使用的主要酵素是粗胰蛋白酶。因此，酵素分解是原代細胞培養分離培養程序中最優選的方法，因為它對細胞的負面影響低且產量高。

使用原代細胞進行 3D 培養的生物醫學研究進展

原代細胞被認為是生物學上真實的，因為它們與原始供體組織幾乎完美匹配。這表明 3D 細胞構建體中使用的原代細胞比細胞株更有能力創建體內多細胞環境的生理相關模擬。原代細胞經常用於 3D 培養，因為它們比傳統細胞株提供更準確的觀察。

增加原代細胞培養在動物細胞的使用

原代細胞培養的成長進一步受到動物源原代細胞在疫苗開發中的廣泛使用的推動。動物細胞，包括小鼠、大鼠和豬，經過充分研究和表徵，是各種科學應用的有用資源。是研究疾病原因、開發新藥、進行毒性試驗的重要模型。

北美預計將佔據主要市場佔有率/原代細胞培養市場的區域分析

由於醫療成本高昂、老年人口不斷增加、慢性病發病率上升以及政府融資增加，預計北美將主導全球原代細胞培養產業。此外，由於幹細胞移植相關成本降低，預計亞太地區將出現強勁成長，導致需求增加和大量研究和開發。再生醫學、幹細胞研究和組織工程應用的重大進展也帶動了亞太地區細胞和基因療法開發和生產的繁榮。

市場主要發展

2023 年 4 月，AnaBios 將收購 Cell Systems，以增加可用於藥物研發研究的人類細胞類型的數量。
2023 年 2 月，賽默飛世爾科技與製造公司 Celltrio 合作，為客戶提供全自動細胞培養系統。
2022年3月，高純度Kupffer細胞將加入BioIVT的人類原代肝細胞庫中，以支持肝病新藥的研發。

In biomedical research, primary cell culture is an essential technique that involves isolating and cultivating cells directly originating from living tissues or organs. Cells are extracted from tissues by dissection or biopsy, and they are then grown in an appropriate medium to retain their physiological significance and original properties. Through increased heterogeneity in the study of varied cell populations, the method offers a more accurate model for comprehending biological processes, pharmacological reactions, and toxicological consequences.

Growth drivers in the primary cell culture market

The main driver fueling the primary cell culture market's expansion is the rising incidence of chronic diseases such as diabetes mellitus, cancer, infections, autoimmune disorders, cardiovascular diseases, and nephrological diseases. Furthermore, increased research efforts as a result of this rise in illness among patients have encouraged the widespread use of primary cell cultures.

Rising utilization in cell and gene therapy development

The need for personalized treatments is rising, which can be linked to the expanding usage of regenerative medicine. This factor is further fueling the primary cell culture industry. The use of cell and gene therapies to treat ailments including cancer, genetic abnormalities, and autoimmune diseases holds considerable promise. The primary cell culture plays a crucial part in their growth. They entail the manipulation and alteration of cells or genes to restore or increase their function.

Growing prevalence of cancer

The necessity for primary cell culture is expanding as a result of the growing prevalence of cancer. . For instance, according to WHO forecasts, by 2030, the number of cancer-related fatalities will have increased to almost 17 million worldwide. Additionally, according to ACS Journals from February 2021, there were 10.2 million cancer-related fatalities and around 19.3 million new cases of cancer globally in 2020. Thus, as cancer rates rise globally, there will be an increasing need for innovative therapies, which is expected to fuel primary cell culture market share.

Increasing preference for enzymatic degradation is anticipated to drive the market

The primary cell culture market share is rising due to a strong preference for the enzymatic degradation method over alternative primary cell separation techniques because of its advantages including decreased culturing damage, quick processing, and high output of a representative sample. With the use of several types of enzymes, the tissue is disaggregated while producing a high output of primary cells. The main enzyme employed in this method is crude trypsin. Enzymatic disaggregation is, therefore, the most favoured approach in primary cell culture separation and culture procedures since it has less of a negative impact on the cells and produces a higher yield.

Advancement in biomedical research in 3D cultures using primary cells

Primary cells are regarded to be biologically realistic due to their almost perfect match to the original donor tissue. This demonstrates that primary cells utilized in 3D cell structures are more capable than cell lines of producing physiologically appropriate simulations of multicellular environments found in vivo. Primary cells are frequently employed in 3D cultures because they yield findings that are more accurate than those of traditional cell lines.

Increasing use of primary cell culture in animal cells

The primary cell culture growth is further being driven by the expanding use of animal-origin primary cells for vaccine development. Since animal cells have been well examined and characterized, including those from mice, rats, and pigs, they are useful resources for a variety of scientific applications. They are crucial models for researching disease causes, creating new drugs, and conducting toxicity tests.

North America is predicted to hold a significant market share/ Regional analysis of primary cell culture market

North America is anticipated to dominate the global primary cell culture industry due to its high healthcare costs, expanding elderly population, rising chronic illness rates, and increased government financing. Moreover, the Asia Pacific region is predicted to experience strong growth as a result of the decreased costs connected with stem cell transplantation in the area, which has increased demand and included significant R&D. With major developments in regenerative medicine, stem cell research, and tissue engineering applications, there has also been a boom in the development and production of cell and gene treatments in Asia Pacific region.

Market Key Developments

In April 2023, AnaBios bought Cell Systems to increase the range of human cells available for drug research.
In February 2023, Thermo Fisher Scientific, Inc. established a partnership with manufacturing firm Celltrio to provide its clients with a fully automated cell culture system.
In March 2022, High-purity Kupffer cells were added to BioIVT's collection of human primary hepatic cells to aid in the research and development of new medications for liver diseases.

Segmentation:

By Product

Primary Cells
Reagents & Supplements
Media

By Separation

Explant Method
Enzymatic Degradation
Mechanical Separation
Others

By Cell Type

Animal Cells
Human Cells

By Application

Cell & Gene Therapy Development
Vaccine Production
Model System
Virology
Prenatal Diagnosis
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. PRIMARY CELL CULTURE MARKET, BY PRODUCT

5.1. Introduction
5.2. Primary Cells
5.3. Reagents & Supplements
5.4. Media

6. PRIMARY CELL CULTURE MARKET, BY SEPARATION

6.1. Introduction
6.2. Explant Method
6.3. Enzymatic Degradation
6.4. Mechanical Separation
6.5. Others

7. PRIMARY CELL CULTURE MARKET, BY CELL TYPE

7.1. Introduction
7.2. Animal Cells
7.3. Human Cells

8. PRIMARY CELL CULTURE MARKET, BY APPLICATION

8.1. Introduction
8.2. Cell & Gene Therapy Development
8.3. Vaccine Production
8.4. Model System
8.5. Virology
8.6. Prenatal Diagnosis
8.7. Others

9. PRIMARY CELL CULTURE MARKET, BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. United States
- 9.2.2. Canada
- 9.2.3. Mexico
9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
9.4. Europe
- 9.4.1. United Kingdom
- 9.4.2. Germany
- 9.4.3. France
- 9.4.4. Spain
- 9.4.5. Others
9.5. The Middle East and Africa
- 9.5.1. Saudi Arabia
- 9.5.2. UAE
- 9.5.3. Israel
- 9.5.4. Others
9.6. Asia Pacific
- 9.6.1. Japan
- 9.6.2. China
- 9.6.3. India
- 9.6.4. South Korea
- 9.6.5. Indonesia
- 9.6.6. Thailand
- 9.6.7. Others